Skip to main content

Table 1 Baseline characteristics

From: Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

Characteristics   FAS (n = 35) Safety/surgery set (n = 32)
Age (years), median (range)   62 (35, 73) 60 (35, 73)
Gender, n (%) Male 27 (77.1%) 26 (81.2%)
Female 8 (22.9%) 6 (18.8%)
ECOG PS, n (%) 0–1 35 (100%) 32 (100%)
Tumor location, n (%) Stomach 24 (68.6%) 21 (65.6%)
GEJ 11 (31.4%) 11 (34.4%)
Histology, n (%) Differentiated type 11 (31.4%) 10 (31.2%)
Undifferentiated type 22 (62.9%) 21 (65.6%)
NOS 2 (5.7%) 1 (3.1%)
Lauren subtype, n (%) Intestinal 18 (51.4%) 17 (53.1%)
Mixed 4 (11.4%) 4 (12.5%)
Diffuse 8 (22.9%) 8 (25.0%)
Unknown 5 (14.3%) 3 (9.4%)
Clinical tumor stage, n (%) cT3 8 (22.9%) 8 (25.0%)
cT4a 27 (77.1%) 24 (75.0%)
Clinical node stage, n (%) cN1 11 (31.4%) 11 (34.4%)
cN2 21 (60.0%) 20 (62.5%)
cN3 3 (8.6%) 1 (3.1%)
  1. FAS full analysis set, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, NOS not otherwise specified